Choice of treatment and adherence to international ESO-ESMO (ABC) guidelines in HR+/HER2-ve metastatic breast cancer (MBC) patients (pts).Marina Elena Cazzaniga, Sabino De Placido, Giorgio Mustacchi et al.|Journal of Clinical Oncology|2017Cited by 1
The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.Giorgio Mustacchi, Emanuela Romagnoli, Filippo Montemurro et al.|Journal of Clinical Oncology|2017Cited by 1